Eagle Pharmaceuticals Inc

+1.38 (+3.20%)

Eagle Pharma Reports Submission Of NDA To U.S. FDA For Landiolol

Published: 06/01/2022 11:53 GMT
Eagle Pharmaceuticals Inc (EGRX) - Eagle Pharmaceuticals Announces Submission of New Drug Application to U.S. Food and Drug Administration for Landiolol, a Beta-1 Adrenergic Blocker.
Eagle Pharmaceuticals Inc - If Landiolol is Approved, Eagle Expects Five Years of New Chemical Entity Exclusivity.
Eagle - Expected Approval Mid-year 2023, If Accepted by FDA for Filing, Based on Feedback From FDA Provided During Aop Health's Type C Meeting.
Eagle Pharmaceuticals - Enrollment of Study of Pediatric Patients With Supraventricular Tachycardia is Underway in Europe.
Eagle Pharmaceuticals- FDA Has Tentatively Agreed That Study Could Form Basis for Proposed Pediatric Study Plans for a Future Submission to FDA.